Search results
Astellas Showcases Scientific Advancements Across its Oncology Portfolio at 2024 ASCO Annual Meeting
WPRI Providence· 2 days agoThe volume of data being presented by Astellas reinforces its commitment to changing the course of cancer treatment through targeted therapies for hard-to-treat cancers ...
Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb
WFRV 5 Green Bay· 6 days agoIn the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the renewal of funding for President Biden's " ...
Amgen plows ahead with costly, highly toxic cancer dosing despite FDA challenge
Chicago Sun-Times· 5 days agoWhen doctors began using the drug sotorasib in 2021 with high expectations for its innovative approach to attacking lung cancer, retired medical technician Don Crosslin was an early beneficiary. Crosslin started the drug that July.
Billionaire Jim Simons Owns These 2 Healthcare Stocks: Should You? | The Motley Fool
The Motley Fool· 2 days agoMany billionaire investors are going all in on artificial intelligence (AI). Consider Renaissance...
Direct transposition of native DNA for sensitive multimodal single-molecule sequencing - Nature...
Nature· 6 days agoTwo low-input tagmentation-based long-read sequencing methods, single-molecule real-time sequencing by tagmentation (SMRT-Tag), which identifies genetic variation and CpG methylation, and single-molecule ...
From the Publisher's Desk: Don’t rob the future
Burnett County Sentinel· 4 days agoIt’s been a year since I received a diagnosis of prostate cancer and surgery to remove my prostate.
TD Cowen Raises BioNTech (NASDAQ:BNTX) Price Target to $98.00
ETF DAILY NEWS· 5 days agoBioNTech (NASDAQ:BNTX – Free Report) had its price objective lifted by TD Cowen from $95.00 to $98.00 in a report published on Tuesday, Benzinga reports. The brokerage currently has a hold rating ...
Janux Therapeutics Reports Narrower Q1 Loss, Misses Revenue Esti
Guru Focus· 7 days agoJanux Therapeutics Inc is at the forefront of developing next-generation therapeutics for cancer treatment. By leveraging its proprietary Tumor Activated T Cell< ...
Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 4 days agoOncternal Therapeutics, Inc. (NASDAQ:ONCT) Q1 2024 Earnings Call Transcript May 9, 2024 Oncternal...
Janux Therapeutics Reports Narrower Q1 Loss, Misses Revenue Estimates
GuruFocus.com via Yahoo Finance· 7 days agoTherapeutics Inc is at the forefront of developing next-generation therapeutics for cancer...